Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/222284
Title: Sutureless Scleral-Fixated Soleko Fil Carlevale Intraocular Lens and Associated Pars Plana Vitrectomy in Aphakia Management: A National Multicenter Audit
Author: Ferrer-alapont, Lorena
Bernal-morales, Carolina
J. Navarro, Manuel
Ruiz-casas, Diego
García-arumí, Claudia
Manuel Cubero-parra, Juan
Vicente Dabad-moreno, Jose
Velázquez-villoria, Daniel
Marticorena, Joaquín
Zarco-bosquet, Julián
Armada-maresca, Félix
Irigoyen, Cristina
Santamaría-Álvarez, Juan-francisco
Carnota-méndez, Pablo
Sánchez-santos, Idaira
Olivier-pascual, Nuria
Javier Ascaso, Francisco
Zarranz-ventura, Javier
Issue Date: 4-Jun-2025
Publisher: MDPI AG
Abstract: Objective: The aim of this study was to evaluate the clinical outcomes of sutureless scleral-fixated (SSF) Soleko Fil Carlevale intraocular lens (SC-IOL) implants associated with pars plana vitrectomy (PPV) in patients with aphakia secondary to complicated cataract surgery or IOL luxation nationwide. Methods: A multicenter, national, retrospective study of 268 eyes (268 patients) which underwent simultaneous PPV and SC-IOL implantation was conducted. Demographics; ocular data; pre-surgical, surgical and post-surgical details; and refractive results were collected. Intra- and postoperative complications and management details were described. Best-corrected visual acuity (BCVA), intraocular pressure (IOP) and central retinal thickness (CRT) were collected at 1 week and at 1, 3, 6 and 12 months post-surgery. Kaplan-Meier curves were constructed to assess the cumulative probability of postoperative BCVA, IOP levels, macular edema (ME) and corneal decompensation. Results: The cumulative probability of final VA <= 0.3 logMAR was 64.4% at 12 months follow-up. The probability of IOP > 21, >= 25 and >= 30 mmHg was 29.8%, 16.9% and 10.1%, respectively, and the cumulative probability of IOP-lowering treatment was 42.3% at 12 months. Glaucoma surgery was required in 3.7% of the eyes (10/268). The cumulative probability of postoperative ME development was 26.6% at 12 months, managed with topical treatment alone (73.5%) and intravitreal injections (26.5%). Corneal transplantation was required in 3.7% of the eyes (10/268). Conclusions: Sutureless scleral-fixated SC-IOL is an adequate therapeutic alternative in the management of aphakia with good visual results and an acceptable safety profile in routine clinical care. Longer-term studies are needed to evaluate its results and complications compared to other therapeutic alternatives.
Note: Reproducció del document publicat a: https://doi.org/10.3390/jcm14113963
It is part of: Journal of Clinical Medicine, 2025, vol. 14, issue. 11, p. 3963
URI: https://hdl.handle.net/2445/222284
Related resource: https://doi.org/10.3390/jcm14113963
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
jcm-14-03963.pdf976.21 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.